Understand any stock in simple English
Enter a ticker to learn what the company does and how it makes money.
CMR Surgical makes and sells the Versius surgical robot, a system that helps surgeons perform soft tissue operations with small keyhole incisions.
CMR Surgical is a British medical device company that builds a surgical robot called Versius. Hospitals buy these robots so their surgeons can perform soft tissue operations โ things like hernia repairs, gallbladder removals, and prostate surgery โ through tiny cuts instead of large open wounds.
The core idea is simple. Traditional open surgery means a big incision, more pain, and a longer recovery. Keyhole surgery, where surgeons work through small ports, is gentler, but holding long instruments steady inside a body is hard on the human hand. Versius is a set of robotic arms that hold and move those instruments with great precision, while the surgeon sits at a console nearby, guiding them with joysticks and watching a magnified 3D view. The robot doesn't do the operation; it translates the surgeon's hand movements into steadier, more controlled motions inside the patient. What makes Versius distinctive is its size. Unlike the bulky robots that dominated this market for years, Versius is built from small, separate arms on a portable cart, so it can fit into ordinary operating rooms rather than requiring a dedicated suite. It's also designed to be modular, letting hospitals start small and add arms as they grow. CMR sells the systems to hospitals and surgical teams, and it makes money both from the hardware and from the instruments and services that keep the robots running.
The company sits in a market long led by Intuitive Surgical Intuitive Surgical, the American giant behind the da Vinci system, which built a huge installed base and deep surgeon loyalty over two decades. CMR's bet is that hospitals want a lower-cost, more flexible alternative. The risk is real: surgical robots are expensive, training surgeons takes time, and the field is crowded with competitors. CMR has raised large amounts of private capital to build manufacturing and expand globally, and it remains a private, venture-backed company rather than a listed one. Its success now hinges on convincing enough hospitals that a smaller, cheaper robot is worth adopting at scale.
Saved answer ยท last researched 16 Nov 2026